NYSE · Biotech stocks database
IQV — IQVIA Holdings Inc.
IQV (IQVIA Holdings Inc.) stock: $267.56, $44.04B market cap, $1.91B cash, $56.12B EV, $48.04B fully diluted market cap. Next expected readout: Feb-27. Data from Fully Diluted's biotech stocks database.
Overview
Assets
Pipeline
Trials
Holders
Enterprise value
$56,120.4M
Balance sheet
Cash $1,909.0M Debt $13,989.0M Net cash -$12,080.0M Enterprise value $56,120.4M Basic shares 164.6M shares Fully diluted shares 179.5M shares Fully diluted market cap $48,038.1M Cash per share $11.60
Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history Loading IQV daily closes…
Loading price history…
Upcoming catalysts Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
No lead program on file for this company.
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT07759544 Not disclosed Not yet recruiting Sponsor IQV — Obesity (Disorder); Overweight , Obesity — NCT04498117 Phase 3 Active, not recruiting Collaborator CanariaBio Inc. — Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer — NCT05908084 Phase 3 Active, not recruiting Collaborator HUMA — End Stage Renal Disease (ESRD) — NCT04877691 Phase 3 Active, not recruiting Collaborator AZN AZN Systemic Lupus Erythematosus — NCT05101187 Phase 3 Active, not recruiting Collaborator F2G Biotech GmbH — Invasive Aspergillosis — NCT05267613 Phase 3 Active, not recruiting Collaborator AZN AZN Erosive Esophagitis — NCT07525427 Phase 2 Recruiting Collaborator Gates Medical Research Institute — Drug Susceptible Pulmonary Tuberculosis — NCT06549946 Phase 2 Recruiting Collaborator Psivac Ltd — Solid Tumor; Head and Neck Cancer — NCT04980638 Phase 2 Recruiting Collaborator EspeRare Foundation — X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) — NCT07430917 Phase 2 Recruiting Collaborator Abrexa Pharmaceuticals, Inc. — Acute Ischemic Stroke — NCT07712484 Phase 2 Not yet recruiting Collaborator F2G Ltd — Coccidioidomycosis; Disseminated Fungal Infection; Coccidioides Infection — NCT02734004 Phase 2 Active, not recruiting Collaborator AZN AZN Ovarian; Breast; SCLC —
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 40 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 41 active trials for IQVIA RDS Spain, SL on ClinicalTrials.gov
No specialist-fund holders in 13F data for this company.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.